Medindia

X

Lifechek Selects Activant Eagle Solution

Tuesday, August 31, 2010 General News J E 4
Advertisement


LIVERMORE, Calif., Aug. 30 Activant Solutions Inc., a leading provider of retail and distribution business management solutions, today announced that Lifechek Drug Inc. has selected the Activant EagleŽ software platform to be its business management and Point-of-Sale (POS) solution. Lifechek executives selected the Activant Eagle solution as part of a greater effort to improve and expand its front store retail business.

The pharmacy marketplace is undergoing a major shift, and independent community pharmacies are looking for ways to grow their retail business and become a primary shopping destination. Many of these pharmacies are finding that a more robust POS and retail business management system is a requirement for significantly improving their retail business performance.

Lifechek Drug is an independent community pharmacy chain with 23 locations throughout Texas. To date, the company has focused on prescription sales - only four of its locations have retail space. Earlier this year, Lifechek executives decided to focus more on its retail business and expand the retail offering in all 23 stores. Because retail had not previously been a point of emphasis for the company, Lifechek had been using the front end POS system that came with its pharmacy management system. Company executives evaluated this system and quickly decided that it would not be sufficient enough to manage Lifechek's expanding multi-store retail needs.

"The Activant Eagle solution is going to play a major part in us becoming better retailers," said Bruce Gingrich, CEO of Lifechek. "We selected the system because it had an unparalleled combination of speed and flexibility. We believe that our clerks will be able to quickly grasp the system and speed our customers through the checkout process. Our managers and executives will benefit from the Eagle system's analytics modules and marketing programs, such as the Gift Card and Loyalty programs."

With the addition of retail space and inventory, Lifechek understands that it will also dramatically increase its inventory costs. The Activant Eagle solution will help Lifechek establish an efficient and effective inventory management program. "The Eagle Purchasing & Receiving system will help us streamline our reordering process and simplify the job of keeping our inventory updated," added Gingrich. "However, inventory management involves more than just keeping merchandise in stock. Activant Eagle's inventory controls will also help us improve other inventory-related functions, such as price updates and loss prevention so that we can get the most from our merchandise investment."

"The Activant Eagle solution will help Lifechek improve almost every aspect of its retail business," said Paul Salsgiver, Executive Vice President for Activant. "From tracking sales, to obtaining merchandise, to manage inventory, to communicating with customers and enhancing their overall shopping experience, we feel that the Activant system will be a key part of elevating Lifechek's retail business."

About Activant Solutions

Activant Solutions Inc. is a leading technology provider of business management solutions serving small- and medium-sized businesses in three primary vertical markets: hardware and lumber, wholesale distribution and the automotive parts aftermarket. Activant provides customers with industry specific software, professional services, content, supply chain connectivity, and analytics. Over 30,000 customer locations use Activant to manage their day-to-day operations. Activant's systems are designed to help customers increase sales, boost productivity, operate more cost-efficiently, improve inventory turns and enhance trading partner relationships. Activant has operations in Texas, California, Colorado, Illinois, Pennsylvania, South Carolina, Utah, Canada, Ireland and the United Kingdom. For more information, please visit www.activant.com.

This announcement relating to Activant may contain statements that are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, such as statements concerning trends, future technology or products, or Activant's execution. These statements are based on current expectations and are subject to risks and uncertainties which could materially affect the company's results, including, without limitation, market demand for products and technology, the company's ability to meet that market demand, the integration of Activant's technology and products with technology and products supplied by others, the integration of Activant's products into the businesses of its customers, customer acceptance of Activant's products, and the retention and deployment of skilled Activant service providers. Except to the extent required by applicable securities laws, we undertake no obligation to update or publicly revise any of the forward-looking statements. Please refer to our most recently filed Quarterly Report on Form 10-Q for the period ended June 30, 2010 and our Annual Report on Form 10-K for the year ended September 30, 2009, each of which have been filed with the Securities Exchange Commission and can be found through the Activant investor relations website at www.activant.com/company/investors for a full discussion of the risks and other factors.

Note: Activant, Activant Eagle, Eagle, and the stylized Activant logo design are registered trademark of Activant Solutions Inc. All other trademarks are the property of their respective owners.

Press Contact: Rick Fernandez Incendio International Tel: 770.973.8401 rick@incendiopr.com

SOURCE Activant Solutions Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Emdeon Commercial MedRx(TM) to Provide Retail Phar...
S
Cell Therapy Foundation Calls for Additional Resea...